Appendix

Table S1. Odds of early menopause (<45 years old) based on self-report with biochemical confirmation of menopause status among women living with HIV (14/83) and HIV-negative women (15/92) in the CARMA-ENDO and BCC3 cohorts

	Unadjusted OR (95% CI)	*p*-value	Adjusted OR (95% CI)	*p*-value
HIV status (ref: HIV-negative)	1.04 (0.47 to 2.32)	0.92	1.35 (0.47 to 3.88)	0.57
Income (ref: ≥20,000 CAD/year)	1.19 (0.52 to 2.69)	0.68	0.63 (0.20 to 1.87)	0.41
Parity (per increase in one birth)	1.03 (0.78 to 1.33)	0.83	0.97 (0.69 to 1.34)	0.87
BMI* (per one kg/m^2 increase)	0.99 (0.93 to 1.05)	0.75	0.98 (0.91 to 1.05)	0.53
Hepatitis C infection (ref: never)	1.29 (0.55 to 2.91)	0.55	0.39 (0.09 to 1.52)	0.18
Smoking (ref: never)				
Past	1.50 (0.46 to 8.57)	0.48	0.61 (0.11 to 2.64)	0.53
Current	**3.20 (1.28 to 8.57)**	**0.02**	2.66 (0.64 to 11.0)	0.17
Substance use† (ref: never)	**2.95 (1.31 to 6.76)**	**0.009**	3.60 (0.97 to 14.5)	0.06
Ethnicity (ref: White)				
Non-White	1.17 (0.52 to 2.63)	0.71		
Age at menarche (per one year increase)	1.15 (0.89 to 1.48)	0.29		

Biochemically confirmed age at menopause was determined based on the age at the last menstrual period and follicle stimulating hormone levels. *BMI=body mass index; †Substance use=history of opioid, crack/cocaine, and/or methamphetamine use.

Table S2. Factors associated with self-report plus biochemically confirmed age at menopause by median regression in women living with HIV (n=66) and HIV-negative women (n=85) in the CARMA-ENDO and BCC3 cohorts who have never used opioids

	Unadjusted β (95% CI)	*p*-value	Adjusted β (95% CI)	*p*-value
HIV status (ref: HIV-negative)	-1.00 (-3.04 to 1.04)	0.33	0.93 (-1.17 to 3.04)	0.38
Income (ref: ≥20,000 CAD/year)	-2.00 (4.47 to 0.47)	0.11	0.41 (-1.53 to 2.36)	0.68
Parity (per increase in one birth)	0.00 (-0.71 to 0.71)	1.00	-0.08 (-0.74 to 0.59)	0.82
BMI* (per one kg/m^2 increase)	0.00 (-0.10 to 0.10	1.00	-0.06 (-0.19 to 0.07)	0.37
Hepatitis C infection (ref: never)	-2.00 (04.45 to 0.45)	0.11	-0.40 (-3.04 to 2.25)	0.77
Smoking (ref: never)				
Past	0.00 (-1.66 to 1.66)	1.00	-0.87 (-3.12 to 1.39)	0.45
Current	**-3.00 (-4.95 to -1.05)**	**<0.001**	**-2.77 (-5.14 to -0.41)**	**0.02**

Substance use† (ref: never)	**-3.00 (-5.80 to -0.20)**	**0.04**	-1.11 (-4.12 to 1.90)	0.47
Age at menarche (per one year increase)	0.00 (-0.51 to 0.51)	1.00	-0.06 (-0.67 to 0.55)	0.85
Ethnicity (ref: White)				
Non-White	-1.00 (-2.88 to 0.88)	0.29		

Biochemically confirmed age at menopause was determined based on the age at the last menstrual period and follicle stimulating hormone levels. *BMI=body mass index; †Substance use=history of crack/cocaine or methamphetamine use.

Table S3. Association between HIV-related variables and self-report with biochemically confirmed age at menopause by median regression among women living with HIV (n=66) who have never used opioids in the CARMA-ENDO and BCC3 cohorts

	Unadjusted β (95% CI)	*p*-value	Adjusted β (95% CI)	*p*-value
Nadir CD4 count (ref: ≥200 cells/ml)				
<200 cells/ml	1.00 (-6.59 to 8.59)	0.79	3.00 (-3.84 to 9.84)	0.37
Current CD4 count (ref: ≥500 cells/ml)				
<500 cells/ml	1.00 (-2.53 to 4.53)	0.57	0.00 (-7.35 to 7.35)	1.00
Highest HIV viral load (ref: <100,000 copies/μl)	1.00 (-1.93 to 3.93)	0.50	-1.00 (-11.3 to 9.29)	0.84
≥100,000 copies/ml				
Current viral load (ref: undetectable)				
Detectable	-2.00 (-8.09 to 4.09)	0.51		
Years lived with HIV (per on year increase)	0.08 (-0.09 to 0.25)	0.37		

Figure S1. Flowchart of reproductive phase classification by self-report alone or self-report with biochemical confirmation based on follicle stimulating hormone levels